Herbert Irving Comprehensive Cancer Center
Ryan Moy, MD

Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University.

Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award.

Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.

Clinical Studies Managed By This Investigator:
Condition Study Title
Solid Tumors [ CLOSED ] Study of ASTX029 in Subjects With Advanced Solid Tumors
Solid Tumors [ CLOSED ] A Study of OBT076 in Women with Recurring and/or Metastatic Solid Tumors
Cancer A Study of BMS-986340 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Cancer [ CLOSED ] A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Cancer [ CLOSED ] Study of BAY 1895344 in Combination with Chemotherapy for Patients with Metastatic Gastrointestinal Cancer
Cancer Study of Investigational Drug (RP-6306) in Patients with Advanced Cancer
Cancer [ CLOSED ] Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors
Cancer Study of RP-6306 in Combination with FOLFIRI in Patients with Advanced Solid Tumors (Colon, Esophageal, or GI Cancer)
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer
Gastrointestinal Study of Domvanalimab and Zimberelimab Alone or in Combination with Chemotherapy in Patients with Upper Gastrointestinal Cancers (UGI)
Cancer [ CLOSED ] Study of SHR-A1904 in Patients with Advanced Solid Tumors
Gastrointestinal Study of DKN-01 in Combination with Tislelizumab & Chemotherapy in Patients with Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer
Cancer Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors
Cancer Study of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors